Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00128167 · ClinicalTrials.gov registry record · Phase 3
Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age
A Phase 3 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,500
- Enrollment target
NCT00128167 is a Phase 3 study that has completed, run by MedImmune. The registered enrollment target is 8,500 participants.
The verdict
NCT00128167, a Phase 3 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,500 participants
- Enrollment target
Study Summary
The primary objective of this study is to estimate the relative efficacy and assess the safety of CAIV-T compared to TIV.
Interventions
- DRUG Liquid CAIV-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,500 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00128167
The ClinicalTrials.gov registry entry for NCT00128167 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liquid CAIV-T is the first listed.
NCT00128167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00128167 about?
NCT00128167 is a clinical study titled "Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age". The primary objective of this study is to estimate the relative efficacy and assess the safety of CAIV-T compared to TIV.
What is the current status of trial NCT00128167?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,500 participants. The study started on 2004-10. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00128167?
The interventions under investigation include: Liquid CAIV-T (DRUG).
Who is sponsoring clinical trial NCT00128167?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.